FIELD: biotechnology.
SUBSTANCE: invention relates to the area of biotechnology, specifically to production of recombinant human growth hormone, and can be used in medicine for treatment of diseases associated with human growth hormone deficiency. The recombinant growth hormone has a unique structure and comprises four functional areas: an area homologous to the amino acid sequence of human growth hormone, an area increasing thermal stability and functional stability of the molecule, an area providing dimerisation of the molecule, and an area providing affinity for the cell membrane.
EFFECT: invention ensures production by recombinant method in E. coli cells of human growth hormone exhibiting improved pharmacokinetics - prolonged activity and retaining biological activity of native growth hormone.
2 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
| PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF GROWTH HORMONE-RELATED DISEASES IN HUMANS | 2019 |
|
RU2802215C2 |
| PEGYLATED COMPOUNDS OF RECOMBINANT HUMAN GROWTH HORMONE | 2009 |
|
RU2530714C9 |
| HYBRID PROTEIN BASED ON RECOMBINANT HUMAN ERYTHROPOIETIN, HAVING PROLONGED ACTION (VERSIONS), AND METHOD OF ITS PRODUCTION | 2013 |
|
RU2515914C1 |
| FUSED GROWTH HORMONE PROTEINS | 2008 |
|
RU2473554C2 |
| COMPOSITION OF STABILIZED GROWTH HORMONE AND METHOD OF ITS PREPARING | 1997 |
|
RU2191029C2 |
| HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS) | 2013 |
|
RU2515913C1 |
| DOUBLE-STRANDED POLYETHYLENE GLYCOL MODIFIED GROWTH HORMONE, PREPARATION METHOD AND USE THEREOF | 2008 |
|
RU2488598C2 |
| USING ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES IN PATIENT WITH INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2008 |
|
RU2489166C2 |
| TREATMENT OF AUTOIMMUNE DISEASES IN PATIENT SUFFERING FROM INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2004 |
|
RU2358762C9 |
